These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2637095)

  • 21. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets.
    Del Guerra S; Marselli L; Lupi R; Boggi U; Mosca F; Benzi L; Del Prato S; Marchetti P
    J Diabetes Complications; 2005; 19(1):60-4. PubMed ID: 15642492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic effects of hypoglycaemic sulphonylureas and antibiotic ionophores upon calcium translocation.
    Couturier E; Malaisse WJ
    Br J Pharmacol; 1980; 71(1):315-20. PubMed ID: 6781574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological characterization of the sulphonylurea receptor in rat isolated aorta.
    Löffler C; Quast U
    Br J Pharmacol; 1997 Feb; 120(3):476-80. PubMed ID: 9031752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mechanisms of action of peroral antidiabetics. Sulfonylurea preparations block the ATP-dependent potassium channels].
    Larsson O; Kindmark H; Bränström R; Berggren PO
    Lakartidningen; 1997 Nov; 94(48):4473-7. PubMed ID: 9424548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Glipizide--a short-acting sulphonylurea derivative].
    Ogonowski J
    Przegl Lek; 1996; 53(9):666-7. PubMed ID: 8992534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
    Gulliford M; Latinovic R
    Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemodynamic and other effects of sulphonylurea drugs on the heart.
    Végh A; Papp JG
    Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S43-53. PubMed ID: 8864640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinically important effects of oral antidiabetic drug interactions].
    Drzewoski J; Kopff B
    Pol Merkur Lekarski; 2000 Sep; 9(51):605-7. PubMed ID: 11126985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects.
    Hey JA; del Prado M; Sherwood J; Kreutner W; Egan RW
    Arzneimittelforschung; 1996 Feb; 46(2):153-8. PubMed ID: 8720304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.
    Prendergast BD
    Clin Pharm; 1984; 3(5):473-85. PubMed ID: 6435940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [40 years of using sulfonylurea derivatives for treatment of diabetes].
    Sieradzki J
    Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of hypoglycemic sulfonylurea preparations on the heart conduction system].
    Pogátsa G; Németh M
    Orv Hetil; 1980 Sep; 121(37):2255-7. PubMed ID: 6780962
    [No Abstract]   [Full Text] [Related]  

  • 33. Sulphonylureas and biguanides do not affect insulin binding in H35 hepatoma cells.
    De Vries CP; van der Veen EA
    Diabetes Res; 1986 Jul; 3(6):307-10. PubMed ID: 3757414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New oral antidiabetic drugs. Synthesis and structure-activity relationships.
    Francia E; Marin A; Verdejo F; Sanchez MS; Morell J
    Boll Chim Farm; 1975 Jul; 114(7):379-92. PubMed ID: 1164447
    [No Abstract]   [Full Text] [Related]  

  • 35. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
    Sadikot SM; Mogensen CE
    Diabetes Res Clin Pract; 2008 Dec; 82(3):391-5. PubMed ID: 18945509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects.
    Courtois P; Sener A; Herbaut C; Turc A; Malaisse WJ
    Res Commun Mol Pathol Pharmacol; 1999 Feb; 103(2):211-22. PubMed ID: 10461687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QSAR study of some anti-hyperglycaemic sulphonylurea drugs.
    Dearden JC; Hewitt M; Rowe PH
    SAR QSAR Environ Res; 2015 Jun; 26(6):439-48. PubMed ID: 26034813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.
    Huupponen R
    Med Toxicol; 1987; 2(3):190-209. PubMed ID: 3298923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Glisolamide, a new sulfanylurea. Pharmacologic characteristics].
    D'Alò G; Dalla Vedova R; Cadel S; Campi G; Wassermann A
    Boll Chim Farm; 1978 Jun; 117(6):348-67. PubMed ID: 743381
    [No Abstract]   [Full Text] [Related]  

  • 40. Solid and solution behavior of sulphonylurea complexes with ions of IIA group metals. Molecular modeling of K[Zn(ClCH4SO2NCONHC3H7)3] and action of zinc-sulphonylurea complexes as hypoglycemic agents.
    Hatzidimitriou AG; Kessissoglou DP; Manoussakis GE; Kourounakis PN; Economidis G
    J Inorg Biochem; 1990 Jul; 39(3):263-76. PubMed ID: 2394999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.